- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00014911
Islet Transplantation for Type 1 Diabetes
Islet Transplantation for Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression (ITN005CT)
The purpose of this study is to test whether the islet cell transplantation procedures and results from a previous study in Edmonton, Canada, can be repeated. The study also is designed to learn more about diabetes control using islet cell transplantation.
This is a Phase I/II study (a study that examines effectiveness and looks for side effects). The transplanting of islet cells has been studied in Type 1 diabetic patients whose blood sugar levels will not stay normal, despite intensive insulin therapy. A recent study conducted in Edmonton, Canada, was able to demonstrate that islet transplantation led to insulin independence in a majority of the patients treated. This study extends the results obtained from the Edmonton study, which used islet transplantation in Type 1 diabetic patients with steroid-free immunosuppression.
Study Overview
Status
Conditions
Detailed Description
This is a Phase I/II study (a study that examines effectiveness and looks for side effects). The transplanting of islet cells has been studied in Type 1 diabetic patients whose blood sugar levels will not stay normal, despite intensive insulin therapy. A recent study conducted in Edmonton, Canada, was able to demonstrate that islet transplantation led to insulin independence in a majority of the patients treated. This study extends the results obtained from the Edmonton study, which used islet transplantation in Type 1 diabetic patients with steroid-free immunosuppression.
Eligible patients were randomly selected from the total pool of people who applied through the Immune Tolerance Network. Patients will receive at least 10,000 "islet equivalents" per kilogram (2.2 pounds) of body weight. This likely will require 2 separate islet infusions from 2 separate donors. Immediately before the first transplant, patients will be given anti-rejection (immune suppressing) drugs, including tacrolimus and sirolimus (orally) and daclizumab (intravenously). The islets will be infused into the liver through a tube placed in the portal vein. Heparin (a medication to prevent blood clots) will be administered with the islet infusion. A longer-acting form of heparin will also be given by daily injections during the next week after each transplant. After surgery, patients will receive insulin intravenously for 24 hours. Patients will have an abdominal ultrasound and blood tests to determine liver function. If fewer than 10,000 islets were transplanted, patients will continue insulin treatment, with the dosages adjusted if necessary to account for the transplanted islets. They will take daclizumab every 2 weeks for 8 weeks and tacrolimus and sirolimus daily. Patients will be given antibiotics to prevent infections. Blood tests to determine how much immunosuppressant drug is in the blood will be performed until the drug is at a stable level. Periodically there will be tests to see if the islet cells are functioning. Blood will be drawn to check drug levels and for other tests routinely. Daily insulin requirements will be checked, and these will be recorded monthly. Patients will be followed for at least 1 year post last islet transplantation. Additional follow-up may be provided at least annually for up to 9 years post first transplantation.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada
- University of Alberta
-
-
-
-
-
Giessen, Germany, 35385
- Justus-Leibig University
-
-
-
-
-
Milan, Italy
- University of Milan
-
-
-
-
-
Geneva, Switzerland
- University of Geneva
-
-
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University
-
-
Washington
-
Seattle, Washington, United States, 98101
- Benaroya Research Institute at Virginia Mason Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Patients may be eligible for this study if they:
- Have had Type 1 diabetes mellitus for more than 5 years, and are exhibiting 1 of the following, despite intensive insulin management efforts: a) hypoglycemic unawareness, as defined by inability to sense hypoglycemia until the blood glucose falls to less than 54 mg/dL; b) metabolic instability, with 2 or more episodes of severe hypoglycemia (defined as an event with symptoms consistent with hypoglycemia in which the patient requires the assistance of another person and which is associated with a blood glucose below 54 mg/dL) or 2 or more hospital visits for diabetic ketoacidosis over the last year; or c) despite efforts at optimal glucose control, progressive secondary complications of diabetes as defined by retinopathy, nephropathy, or neuropathy.
- Are 18 to 65 years of age.
Exclusion Criteria
Patients will not be eligible for this study if they:
- Have had severe cardiac disease as defined by: a) recent myocardial infarction within the past 6 months; b) angiographic evidence of non-correctable coronary artery disease; or c) evidence of ischemia on a functional cardiac exam.
- Actively abuse alcohol or substances, including cigarette smoking (must not have smoked within the last 6 months).
- Have psychiatric problems that prevent them from being a suitable candidate for transplantation (such as schizophrenia, bipolar disorder, or major depression that is not controlled or stable on current medication).
- Have a history of not following prescribed regimens.
- Have active infection including hepatitis C virus, hepatitis B virus, human immunodeficiency virus (HIV), or Tuberculosis (TB) (or under treatment for suspected TB).
- Have a history of malignancy, except squamous or basal skin cancer.
- Weigh more than 70 kilograms or have a Body Mass Index (BMI) greater than 26 kg/m^2 at time of screening.
- Have a C-peptide value of 0.3 ng/ml or more following a 5.0 gram intravenous arginine infusion challenge.
- Are unable to provide informed consent.
- Have gallstones or hemangioma in liver.
- Have untreated proliferative retinopathy.
- Are breast-feeding or pregnant, or intend to try and become pregnant (females) or to father a child (males), or fail to follow birth control methods.
- Have had a previous transplant, or evidence of anti-human leukocyte antigen (HLA) antibody.
- Have an insulin requirement of more that 0.7 International Units (IU)/kilograms/day.
- Have a blood glycosylated hemoglobin (HbA1c) higher than 12 percent.
- Are unable to reach the hospital for transplantation within 2 hours of notification.
- Have untreated or treated hyperlipidemia.
- Have a medical condition requiring chronic use of steroids.
- Use coumadin or other anticoagulants (aspirin is allowed).
- Have Addison's disease.
- Have a negative screen for Epstein-Barr virus (EBV).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Islet Transplantation
All study participants
|
Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion.
Up to three transplants are possible depending on individual results.
Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation.
Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks).
Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
An antibacterial used to prevent opportunistic infections
An antiviral used to kill viruses and stop viral replication
An antibacterial used to prevent opportunistic infections
An antiprotozoal used to prevent disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation.
Time Frame: One year status post participant receipt of final islet transplantation
|
Insulin independence: exogenous insulin not required and glycemic control is achieved as defined by maintaining 1.) a blood glycosylated hemoglobin (HbA1c) level < 6.5% (Normal:<5.7%;
pre-diabetes: 5.7% -6.4%; diabetes: 6.5% or higher),2) a blood glucose level after an overnight fast not exceeding 140 mg per deciliter (dL) more than three times in any week (Normal: 70 to 120 mg/dL), and 3)not exceeding a 2-hour postprandial blood glucose level of 180 mg/dL more than four times per week (Normal: <140mg/dL if <=50 years of age, <150 mg/dL for ages 50-60 years and <160 mg/dL for ages 60+)
|
One year status post participant receipt of final islet transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Participants With Partial Islet Function One Year Post Final Islet Transplantation.
Time Frame: One year post receipt of final islet transplantation
|
Partial islet function definition: a fasting basal C-peptide level >= 0.3 ng/mL and a continuing need for insulin or suboptimal glycemic control (Note: C-peptide is a substance that the pancreas releases into the bloodstream in equal amounts to insulin, thereby showing how much insulin the body is making).
Adequate glycemic control is defined by: 1) a blood HbA1c level <6.5%, 2) a blood glucose level after an overnight fast not exceeding 140 mg/dL more than three times in any week and, 3) a 2-hour postprandial blood glucose level not exceeding 180 mg/dL more than four times per week
|
One year post receipt of final islet transplantation
|
Percent of Participants That Achieved Insulin Independence From First Transplant
Time Frame: First transplantation until end of study (up to six years post final transplantation)
|
Insulin independence: exogenous insulin not required and glycemic control is achieved as defined by maintaining 1) a blood glycosylated hemoglobin (HbA1c) level < 6.5% (Normal:<5.7%;
pre-diabetes: 5.7% -6.4%; diabetes: 6.5% or higher),2) a blood glucose level after an overnight fast not exceeding 140 mg per deciliter (dL) more than three times in any week (Normal: 70 to 120 mg/dL), and 3)not exceeding a 2-hour postprandial blood glucose level of 180 mg/dL more than four times per week (Normal: <140mg/dL if <=50 years of age, <150 mg/dL for ages 50-60 years and <160 mg/dL for ages 60+)
|
First transplantation until end of study (up to six years post final transplantation)
|
Percent of Participants With Detectable Fasting Basal C-Peptide Levels
Time Frame: Two years post first transplantation
|
C-peptide is a substance that the pancreas releases into the bloodstream in equal amounts to insulin, thereby showing how much insulin the body is making.
C-peptide secretion is used to measure the function of transplanted islets.
Higher levels indicate better islet function.
Detectable fasting basal levels of C-peptide secretion are >=0.3
ng/ml.
|
Two years post first transplantation
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: James Shapiro, MD, PhD, University of Alberta
Publications and helpful links
General Publications
- Brennan DC, Shannon MB, Koch MJ, Polonsky KS, Desai N, Shapiro J. Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation. Transplantation. 2004 Jul 15;78(1):172-3. doi: 10.1097/01.tp.0000128332.71657.ea. No abstract available.
- Benedini S, Ermetici F, Briganti S, Codella R, Terruzzi I, Maffi P, Caldara R, Secchi A, Nano R, Piemonti L, Alejandro R, Ricordi C, Luzi L. Insulin-mimetic effects of short-term rapamycin in type 1 diabetic patients prior to islet transplantation. Acta Diabetol. 2018 Jul;55(7):715-722. doi: 10.1007/s00592-018-1141-z. Epub 2018 Apr 13.
- Gala-Lopez B, Kin T, O'Gorman D, Pepper AR, Senior P, Humar A, Shapiro AM. Microbial contamination of clinical islet transplant preparations is associated with very low risk of infection. Diabetes Technol Ther. 2013 Apr;15(4):323-7. doi: 10.1089/dia.2012.0297. Epub 2013 Feb 25.
- Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006 Sep 28;355(13):1318-30. doi: 10.1056/NEJMoa061267.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antibiotics, Antineoplastic
- Antifungal Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Folic Acid Antagonists
- Trypanocidal Agents
- Calcineurin Inhibitors
- Anti-Dyskinesia Agents
- Anti-Infective Agents, Urinary
- Renal Agents
- Cytochrome P-450 CYP2C8 Inhibitors
- Tacrolimus
- Sirolimus
- Trimethoprim
- Sulfamethoxazole
- Daclizumab
- Ganciclovir
- Ganciclovir triphosphate
- Pentamidine
Other Study ID Numbers
- DAIT ITN005CT (DAIT NIS01)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Individual Participant Data Set
Information identifier: SDY567Information comments: ImmPort study identifier is SDY567. ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts and is available to the Public.
-
Study summary, -schematic, -design, -adverse event(s),-medications,-demographics, - lab tests, -study files
Information identifier: SDY567Information comments: ImmPort study identifier is SDY567. ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts and is available to the Public.
-
Individual Participant Data Set
Information identifier: ITN005CTInformation comments: TrialShare is the Immune Tolerance Network (ITN) portal that makes data from the consortium's clinical trials publicly available without charge. Creating an account for ITN TrialShare is free and allows for searching studies of interest.
-
Study overview & protocol synopsis, -navigator, -schedule of assessments, -data&reports, -specimens, etc.
Information identifier: ITN005CTInformation comments: TrialShare is a clinical trials research portal developed by the Immune Tolerance Network (ITN) that makes data from the consortium's clinical trials publicly available without charge.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Insulin-Dependent
-
VeraLight, Inc.CompletedDiabetes Mellitus, Non-Insulin DependentUnited States
-
Procter and GambleTerminatedNon-Insulin-dependent Diabetes MellitusUnited States
-
Inha University HospitalCompletedNon Insulin Dependent Diabetes MellitusKorea, Republic of
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
VeraLight, Inc.CompletedDiabetes Mellitus, Non-Insulin DependentUnited States
-
Samsung Medical CenterMinistry of Trade, Industry & Energy, Republic of Korea; Korea Evaluation Institute... and other collaboratorsCompletedDiabetes Mellitus | Insulin-dependent Diabetes Mellitus | Insulin HypoglycemiaKorea, Republic of
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedDiabetes Mellitus, Type II | Diabetes Mellitus, Non Insulin DependentUnited States, Poland, Bulgaria, India, Malaysia, Romania, Canada, Russian Federation, Argentina, Puerto Rico, Czech Republic, United Kingdom, Mexico
-
Merck Sharp & Dohme LLCCompletedDiabetes Mellitus, Non-Insulin-Dependent | Type 2 Diabetes Mellitus, Non Insulin Dependent
-
National Center for Complementary and Integrative...CompletedDiabetes Mellitus, Non-Insulin Dependent | Non-Insulin DependentUnited States
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
Clinical Trials on Islet Transplantation
-
University Hospital, LilleCompletedIslet TransplantationFrance
-
Rodolfo AlejandroNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedDiabetes Mellitus, Type 1United States
-
The Nordic Network For Clinical Islet TransplantationUnknownType 1 Diabetes | End Stage Renal Disease
-
Rodolfo AlejandroJuvenile Diabetes Research Foundation; Diabetes Research Institute FoundationActive, not recruitingHypoglycemia | Type 1 Diabetes Mellitus | Hypoglycemia UnawarenessUnited States
-
National Institute of Diabetes and Digestive and...Completed
-
Frantisek SaudekRecruitingIslets of Langerhans TransplantationCzechia
-
Weill Medical College of Cornell UniversityTerminated
-
National Center for Research Resources (NCRR)UnknownDiabetes Mellitus
-
National Institute of Diabetes and Digestive and...CompletedDiabetes Mellitus, Type 1United States
-
Baylor Research InstituteUniversity of Miami; Baylor Health Care SystemCompleted